How Analysts Feel About Acer Therapeutics Inc. (ACER)?


As of Friday close, Acer Therapeutics Inc.’s (NASDAQ:ACER) stock was down -$0.88, moving down -56.77 percent to $0.67. The average number of shares traded per day over the past five days has been 980,740 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.0000 fall in that time frame. In the last twenty days, the average volume was 314,070, while in the previous 50 days, it was 397,684.

Since last month, ACER stock retreated -67.94%. Shares of the company fell to $0.6500 on 03/17/23, the lowest level in the past month. A 52-week high of $4.56 was reached on 01/12/23 after having rallying from a 52-week low of $1.11. Since the beginning of this year, ACER’s stock price has dropped by -73.31% or -$1.8400, and marked a new high 6 times. However, the stock has declined by -85.31% since its 52-week high.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


ACER stock investors should be aware that Acer Therapeutics Inc. (ACER) stock had its last reported insider trading activity 109 days ago on Nov 29. Schelling Chris, the President & CEO of the company, purchased of 819,672 shares for $1.22 on Nov 29. It resulted in a $1,000,000 investment by the insider. ASELAGE STEVE added 409,836 shares at an average price of $1.22 on Nov 29. The insider now owns 483,741 shares following the transaction.

Financial Health

In the three months ended September 29, Acer Therapeutics Inc.’s quick ratio stood at 0.40, while its current ratio was 0.40, showing that the company is not able to pay off its debt. Based on annual data, ACER earned $17.21 million in gross profit and brought in $1.26 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 902.80%. Return on equity (ROE) for the past 12 months was 259.30%.

While analysts expected Acer Therapeutics Inc. to report -$0.68 quarterly earnings, the actual figure was -$0.31 per share, beating the consensus estimate by 54.40%. During the quarter, the company generated -$5.22 million in EBITDA. The liabilities of Acer Therapeutics Inc. were 27.53 million at the end of its most recent quarter ended September 29, and its total debt was $8.37 million. The value of shareholders’ equity is $16.37 million.

Technical Picture

This quick technical analysis looks at Acer Therapeutics Inc.’s (ACER) price momentum. With a historical volatility rate of 398.10%, the RSI 9-day stood at 7.26% on 17 March.

With respect to its five-day moving average, the current Acer Therapeutics Inc. price is down by -59.88% percent or -$1.0000. At present, ACER shares trade -69.82% below its 20-day simple moving average and -44.63% percent below its 100-day simple moving average. However, the stock is currently trading approximately -75.00% below its SMA50 and -71.97% below its SMA200.

Stochastic coefficient K was 4.68% and Stochastic coefficient D was 7.84%, while ATR was 0.2139. Given the Stochastic reading of 1.37% for the 14-day period, the RSI (14) reading has been calculated as 13.22%. As of today, the MACD Oscillator reading stands at -0.2978, while the 14-day reading stands at -0.4459.

Analyst Ratings

H.C. Wainwright reiterated its a Buy rating on Acer Therapeutics Inc. (NASDAQ: ACER) in a note to investors. The analysts firm has however raised their price target to $10, representing a possible 98.78% increase in the stock price. Acer Therapeutics Inc. (ACER) has been rated Buy by analysts. According to 0 brokerage firms, ACER is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Acer Therapeutics Inc. stock as buy, with 3 recommending it as overweight.

With a median target price of $10.00, the current consensus forecast for the stock is $7.00 – $12.00. Based on these forecasts, analysts predict Acer Therapeutics Inc. (ACER) will achieve an average price target of $9.67.


Please enter your comment!
Please enter your name here